SARC022: A Phase 2 Study of OSI-906 in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors
The purpose of this study is to determine the effects (good and/or bad) of OSI-906 on patients diagnosed with wild-type Gastrointestinal Stromal tumors (GIST) cancer.
1. Male or female age 18 or older
2. Confirmed diagnosis of GIST with wild-type genotype
3. For patients diagnosed with GIST at age 18 or younger, must have received Sutent (Sunitinib) as a prior treatment regimen
4. For patients diagnosed with GIST at age 19 or older, must have received Gleevec (Imatinib) as a prior treatment regimen
18 - 100
Healthy Volunteers Needed
Duration of Participation
Until disease progression or unacceptable side effect
Tracy Walker, RN
Cancer Therapy Evaluation Program (CTEP) and the National Cancer Institute (NCI) and SARC (Sarcoma Alliance for Research through Collaboration) is the Coordinating Center.